Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (NCT05564377)
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
🩺 Plain-English Summary (8th-Grade Level)
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
🧪 Interventions in This Study
- Alpelisib (DRUG)
- Binimetinib (DRUG)
- Fluorouracil (DRUG)
- Fulvestrant (DRUG)
- Ipatasertib (DRUG)
- Leucovorin (DRUG)
- Neratinib Maleate (DRUG)
- Nilotinib Hydrochloride Monohydrate (DRUG)
- Olaparib (DRUG)
- Oxaliplatin (DRUG)
- Paclitaxel (DRUG)
- Palbociclib (DRUG)
- Panitumumab (BIOLOGICAL)
- Selumetinib Sulfate (DRUG)
- Sotorasib (DRUG)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (482 Sites)
Showing the first 25 of 482 sites.
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
- Alaska Women's Cancer Care — Anchorage, Alaska
- CTCA at Western Regional Medical Center — Goodyear, Arizona
- Kingman Regional Medical Center — Kingman, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
- PCR Oncology — Arroyo Grande, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Epic Care-Dublin — Dublin, California
- Mercy Cancer Center - Elk Grove — Elk Grove, California
- UC San Diego Health System - Encinitas — Encinitas, California
- UC San Diego Moores Cancer Center — La Jolla, California
- The Angeles Clinic and Research Institute - West Los Angeles Office — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Contra Costa Regional Medical Center — Martinez, California
- Children's Hospital of Orange County — Orange, California
- Saint Joseph Hospital - Orange — Orange, California
- Stanford Cancer Institute Palo Alto — Palo Alto, California
- VA Palo Alto Health Care System — Palo Alto, California
- Mercy Cancer Center - Rocklin — Rocklin, California
- Mercy Cancer Center - Sacramento — Sacramento, California
- UC San Diego Medical Center - Hillcrest — San Diego, California
- Sharp Memorial Hospital — San Diego, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Malignant Solid Neoplasm
- Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer — New Brunswick, New Jersey
- Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer — Houston, Texas
- Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic — Houston, Texas
- Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin — Duarte, California
- Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors — Houston, Texas
- Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study — Houston, Texas
Explore by condition: All Advanced Malignant Solid Neoplasm clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.